Tolerance of nasal and oral povidone-iodine antisepsis amid COVID-19 pandemic

Frank et al., Otolaryngology - Head and Neck Surgery, 165:89, Oct 2021

PVP-I for COVID-19

13th treatment shown to reduce risk in February 2021, now with p = 0.0000000037 from 21 studies.

No treatment is 100% effective.
Protocols combine treatments.

Prospective study of 42 otolaryngology and dental patients, showing low-dose nasal and oral PVP-I solutions to be well-tolerated.
Frank et al., 3 Oct 2021, preprint, 6 authors.